Primary prevention and coronary heart disease: the economic benefits of lowering serum cholesterol.

We examined the expected economic benefits of cholesterol lowering for adult men with significant elevations of total serum cholesterol (above 260 mg/dl), incorporating estimates of direct benefits from anticipated reductions in lifetime expenditures for medical care, and estimates of indirect benefits related to extension of work-life secondary to reductions in morbidity and premature mortality. Our findings yield discounted lifetime direct benefits of a 15 per cent reduction in total serum cholesterol of $3 to $208 per person, and discounted lifetime indirect benefits of $1 to $8,946. Benefits increase with an individual's initial cholesterol level and decrease with the age at which an intervention is initiated. Economic benefits increase approximately twofold in the presence of other coronary risk factors, such as cigarette smoking and hypertension. Results suggest that cholesterol-lowering interventions, no matter what their cost, are unlikely to result in substantial direct savings to the health care system. However, the indirect benefits of intervention are quite high for young and middle-aged adults, as well as for those with severe elevations of cholesterol or with additional coronary risk factors.

[1]  J. Avorn Benefit and cost analysis in geriatric care. Turning age discrimination into health policy. , 1984, The New England journal of medicine.

[2]  L. Kuller,et al.  Epidemiological Study of Sudden and Unexpected Deaths due to Arteriosclerotic Heart Disease , 1966, Circulation.

[3]  W. Friedewald,et al.  Clofibrate in ischemic heart disease. , 1972, Annals of internal medicine.

[4]  H. Smits,et al.  DRGs and the future of surgical practice. , 1984, The New England journal of medicine.

[5]  W. Kannel The role of cholesterol in coronary atherogenesis. , 1974 .

[6]  J. Stamler Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[7]  K. McPherson,et al.  Will payment based on diagnosis-related groups control hospital costs? , 1984, The New England journal of medicine.

[8]  W. Kannel,et al.  The unrecognized myocardial infarction. Fourteen-year follow-up experience in the Framingham study. , 1970, Geriatrics.

[9]  J. Stamler,et al.  George Lyman Duff Memorial Lecture. Lifestyles, major risk factors, proof and public policy. , 1978, Circulation.

[10]  E. Cook,et al.  The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. , 1984, Annals of internal medicine.

[11]  W. Kannel,et al.  Prognosis after initial myocardial infarction: the Framingham study. , 1979, The American journal of cardiology.

[12]  R. Levy The decline in cardiovascular disease mortality. , 1981, Annual review of public health.